DSIP
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring peptide first isolated from the blood of sleeping rabbits in the 1970s, studied for its potential role in promoting deep (delta-wave) sleep.
- Studied for effects on deep (delta-wave) sleep
- One of the earliest-identified endogenous sleep peptides
- Under FDA review for potential compounding status
No commitment · Cancel anytime · Physician evaluation required
About DSIP
DSIP was isolated from cerebral venous blood of sleeping rabbits in 1977 and has been studied off and on for five decades, primarily for a hypothesized role in delta-wave (deep) sleep regulation — though, unusually for an endogenous peptide discovered this long ago, its exact mechanism is still not fully resolved.
What the research shows — and its limits
Human research on DSIP is sparse and dates mostly to small European pilot studies in the 1980s, with more recent research including a blood-brain-barrier fusion study from a Chinese research group. Modern, well-controlled human trials are essentially absent from the current literature. This puts DSIP in a similar evidence category to Semax and Selank — a plausible preclinical mechanism and a small, geographically narrow body of older human data, but not the kind of Phase 3 trial base that exists for FDA-approved sleep medications.
Regulatory note
As of mid-2026, DSIP (referenced as Emideltide) is among several peptides under review by the FDA's Pharmacy Compounding Advisory Committee for potential inclusion on official compounding substance lists.
Who it's for
DSIP is generally considered by adults interested in sleep quality support as part of a broader wellness program, with a clear understanding that the modern clinical trial base is thin.
How It's Administered
DSIP is typically administered as a subcutaneous injection before bedtime. Your physician will determine an appropriate protocol during your evaluation.
Safety & Considerations
Available data from historical human use has not identified significant safety concerns, but the body of evidence is small and dated relative to modern clinical trial standards. Your physician will review your health history during your evaluation, and this program is not appropriate for everyone.
Selected References
The following peer-reviewed sources informed the summary above. Evidence quality varies — some reflect large controlled human trials, others early-stage or animal research, as noted.
- Compare Semax, Selank & DSIP — evidence base and regional research concentration summary
NewGen Peptides research guide, 2026